Hanmi Financial Corp. Announces Participation at Upcoming Virtual Investor Conferences
Get Alerts HAFC Hot Sheet
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 6.3%
Revenue Growth %: -11.8%
Join SI Premium – FREE
LOS ANGELES, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”), the holding company for Hanmi Bank (the “Bank”), today announced that they will participate in the following upcoming virtual investor conferences:
- The Janney Virtual Bank CEO Forum, to be held February 3-4, 2021. The Company will be participating in one-on-one meetings with investors.
- The KBW Virtual Winter Financial Services Symposium, to be held February 10-12, 2021. The Company will be participating in one-on-one meetings with investors.
- The Piper Sandler Virtual Western Financial Services Conference, to be held March 2, 2021. The Company will be participating in one-on-one meetings with investors.
Conference participation is by invitation only and registration is mandatory. For more information on the conference or to schedule a one-on-one meeting, please contact a Janney, KBW or Piper Sandler representative.
About Hanmi Financial Corporation Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 35 full-service branches and 9 loan production offices in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia. Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses. Additional information is available at www.hanmi.com.
Contact:
Romolo (Ron) SantarosaSenior Executive Vice President & Chief Financial Officer213-427-5636
Lasse GlassenInvestor RelationsAddo Investor Relations310-829-5400
Source: Hanmi BankSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Perceptyx Launches Activate, HR’s Missing Link Between Employee Insight and Impact
- CGG: Availability of the preparatory documents for the Combined General Meeting
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!